Navigation Links
OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
Date:2/14/2009

SACRAMENTO, Calif., Feb. 14 /PRNewswire-FirstCall/ -- The Amgen Tour of California, known as "America's largest and most prestigious cycling event," is a 750-mile race that will begin on February 14th in Sacramento and end on February 22nd in Rancho Bernardo. For the first time, the race will include Team Type 1, a team that includes two members with Type 1 diabetes. Thanks to the OmniPod(R) Insulin Management System, Team Type 1 members Phil Southerland and Fabio Calabria will be able to concentrate on competing, rather than insulin injections and blood glucose monitoring, because they will be wearing their OmniPods during the race.

"Our goal is to show the world that people with diabetes can do everything those without diabetes can," said Calabria, who was diagnosed with Type 1 diabetes at the age of 13 and feared the condition might bring an end to his promising athletic career as a cyclist. "I am lucky to be armed with the OmniPod System which allows me to easily deliver the insulin I need to compete with the best cyclists in the world."

The OmniPod System consists of two wireless components: the Pod - a compact, lightweight, self-adhesive insulin delivery device that is worn discreetly on the skin beneath clothing; and the Personal Diabetes Manager - a wireless, menu-driven, hand-held device that programs the Pod.

"While racing, I am able to keep my Personal Diabetes Managers in the car that follows us. This is a major advantage over traditional insulin pump systems, with which you have to carry the machine at all times," Calabria explained.

About the OmniPod Insulin Management System

The OmniPod(R) Insulin Management System is the first and only continuous insulin delivery system of its kind on the market. The OmniPod System offers people living with insulin-dependent diabetes all the benefits of insulin pump therapy, with unprecedented freedom, comfort and ease in ma
'/>"/>

SOURCE Insulet Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM)
2. Fat on chest and upper back increases risk of insulin resistance
3. Scientists explain how insulin secreting cells maintain their glucose sensitivity
4. Smart insulin nanostructures pass feasibility test, UT study reports
5. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
6. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
7. Landmark trial to evaluate cardioprotective properties of insulin
8. Medtronic Mediterranean Launches Worlds First Arabic-Language Integrated Insulin Therapy for Improved Diabetes Management
9. BCP Veterinary Pharmacy Helps Cure Diabetic Cats with BCP PZI(R), the Closest Match to Feline Insulin Available
10. Living donors may be best source of insulin-producing islets for diabetes treatment
11. Insulin regulates the secretion of the antiaging hormome Klotho
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 October is national ... and early detection plans while raising money for breast ... Breast Cancer Awareness Month in the effort to ... to promote the importance of having access to clean, ... may be linked to certain forms of cancer. ...
(Date:10/1/2014)... Two bicyclists began a journey on September 8, ... an effort to raise funds and awareness to the ... father-daughter team, plan to bike more than 4,000 miles ... in Key West Florida. Funds raised along their ... nonprofit organization that assists post-9/11 service members, their families, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 This October, ... to consumer lab testing, is offering 10% off all ... DIBN10 when placing their order to save. The Center ... the United States are affected by Diabetes. Because many ... to go undiagnosed until it causes serious health problems. ...
(Date:10/1/2014)... The Oliver Law Group P.C. ... Other-Sonic Ultrasound Gel lawsuit web page to ... surrounding the 2011 Pseudomonas aeruginosa / bacterial infection ... Michigan, which was ultimately traced to the recalled ... Beaumont patients who allegedly became ill following exposure ...
(Date:10/1/2014)... The annual Social Security cost-of-living adjustment (COLA) ... a new forecast by The Senior Citizens League (TSCL) ... (CPI) data through August, TSCL forecasts that COLAs will be ... consecutive year of record low COLAs,” states TSCL Chairman, Ed ... in 1975,” he notes. , Over the past five years ...
Breaking Medicine News(10 mins):Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... Today, Functionalab, a revolutionary new line of health and ... Bendel on 5th Avenue in New York City. ... in partnership with a globally recognized developer of science-based ... quality, potency and effectiveness. , , ...
... Misonix, Inc. (Nasdaq: MSON ), a developer of ... used for the ablation of tumors and worldwide for other ... and nine months ended March 31, 2009. Michael A. ... Senior VP and Chief Financial Officer, will host a conference ...
... increase patient access to stroke specialists, especially in rural ... (TIA), once known as a "mini" or "warning" stroke, ... full-blown stroke, according to two separate scientific statements and ... of the American Heart Association . , Telemedicine ...
... Inc. (OTC Bulletin Board: DSCI), a provider of ... quarter 2009 results before market on Monday, May 18, 2009. ... day to discuss the results at 11:00 am EDT. Interested ... 98098954 to access the call. You may also access this ...
... option maximizes UHPLC or HPLC productivity via seamless ... all new and existing Corona detector customersCHELMSFORD, Mass., ... UHPLC detector with a Waters ACQUITY UPLC(R) ... a new Empower 2/Corona detector instrument-control software driver. ...
... Co., Inc., (NYSE Amex: TPI ), a ... in Chengdu, China, today,announced that management will hold a ... 11:00 a.m. EDT on Friday, May 15, 2009. Financial,results ... market closes. , Interested parties ...
Cached Medicine News:Health News:Functionalab Launches Exclusively at Henri Bendel Monday, May 11th, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 3Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 4Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 5Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 6Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 7Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 8Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 9Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 10Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3Health News:Derma Sciences Announces Date of Its First Quarter 2009 Earnings Release and Conference Call 2Health News:ESA's Corona(R) Family of HPLC Detectors, Including the New Corona ultra(TM), Can Now be Controlled by Waters Empower(R) 2 Chromatography Software 2Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT 2
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... conducting this study is to provide an overview ... global market for protein drugs/therapeutics. The key objective ... direction of protein drugs as an important tool ... report explores present and future strategies within the ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... BOSTON, Dec. 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) ... continued growth in 2012 through the development and sales ... treatment and management of medical conditions. In 2011, Solos ... approximately $300,000 in debt for the Company. The signed ...
... Dec. 29, 2011 Janssen Research & Development, LLC (JRD) ... Application (sNDA) to the U.S. Food and Drug Administration (FDA) ... an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular ... The filing is supported by data from the pivotal Phase ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: